newsfilter
← Latest News
Business Wire·

Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program

At Nov. 9 Event, Management and Key Opinion Leaders to Review Detailed FX-322 Clinical Study Results in Patients with Sensorineural Hearing Loss (SNHL) and Design of New FX-322-208 Phase 2b Study Company to Introduce a Second Hearing Restoration Prog